Osteoarthritis - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Osteoarthritis - Pipeline Review, H2 2016

Osteoarthritis - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Osteoarthritis - Pipeline Review, H2 2016
Published Aug 24, 2016
281 pages — Published Aug 24, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Osteoarthritis - Pipeline Review, H2 2016, provides an overview of the Osteoarthritis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Osteoarthritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Osteoarthritis and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Osteoarthritis
- The report reviews pipeline therapeutics for Osteoarthritis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Osteoarthritis therapeutics and enlists all their major and minor projects
- The report assesses Osteoarthritis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Osteoarthritis


Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Osteoarthritis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Osteoarthritis pipeline depth and focus of Indication therapeutics
-

  
Source:
Document ID
GMDHC8387IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents216
  List of Tables152
  List of Figures171
Introduction181
  Global Markets Direct Report Coverage181
Osteoarthritis Overview191
Therapeutics Development202
  Pipeline Products for Osteoarthritis Overview201
  Pipeline Products for Osteoarthritis Comparative Analysis211
Osteoarthritis Therapeutics under Development by Companies225
Osteoarthritis Therapeutics under Investigation by Universities/Institutes271
Osteoarthritis Pipeline Products Glance283
  Late Stage Products281
  Clinical Stage Products291
  Early Stage Products301
Osteoarthritis Products under Development by Companies316
Osteoarthritis Products under Investigation by Universities/Institutes371
Osteoarthritis Companies Involved in Therapeutics Development3856
  A. Menarini Industrie Farmaceutiche Riunite Srl381
  AbbVie Inc391
  Abiogen Pharma S.p.A.401
  Ablynx NV411
  Achelios Therapeutics, Inc.421
  Addex Therapeutics Ltd431
  Amgen Inc.441
  Amura Holdings Limited451
  Arcarios BV461
  Asahi Kasei Pharma Corp.471
  Asklepios BioPharmaceutical, Inc.481
  Astellas Pharma Inc.491
  Asterias Biotherapeutics, Inc.501
  Biopharm GmbH511
  Bone Therapeutics SA521
  Can-Fite BioPharma Ltd.531
  Cardax Pharmaceuticals, Inc.541
  Cellceutix Corporation551
  Cellular Biomedicine Group, Inc.561
  Evgen Pharma Plc571
  Galapagos NV581
  Genequine Biotherapeutics GmbH591
  GlaxoSmithKline Plc601
  IntelliCell BioSciences Inc.611
  Jeil Pharmaceutical Co., Ltd.621
  Jenrin Discovery, Inc.631
  K-Stemcell Co., Ltd.641
  Levolta Pharmaceuticals, Inc.651
  Medivir AB661
  Merck KGaA671
  Mesoblast Limited681
  Mor Research Application Ltd691
  NicOx S.A.701
  Nordic Bioscience A/S711
  Novartis AG721
  Omeros Corporation731
  Ono Pharmaceutical Co., Ltd.741
  OrthoCyte Corporation751
  Osteologix Holdings Plc.761
  Pfizer Inc.771
  Pharmalink AB781
  Philogen S.p.A.791
  PLx Pharma Inc.801
  ProteoThera, Inc.811
  Regeneus Ltd821
  Seikagaku Corporation831
  STELIS Biopharma Pvt. Ltd.841
  Symic Biomedical, Inc.851
  Takeda Pharmaceutical Company Limited861
  TissueGene, Inc.871
  Upsher-Smith Laboratories, Inc.881
  Yooyoung Pharmaceutical Co., Ltd.891
  Yuhan Corporation901
  Yungjin Pharm. Co., Ltd.911
  Zimmer Biomet Holdings, Inc.921
  Zynerba Pharmaceuticals, Inc.931
Osteoarthritis Therapeutics Assessment9414
  Assessment by Monotherapy Products941
  Assessment by Combination Products951
  Assessment by Target964
  Assessment by Mechanism of Action1004
  Assessment by Route of Administration1042
  Assessment by Molecule Type1062
Drug Profiles108148
  (apocynin + paeonol) Drug Profile1081
  (clodronate disodium + hyaluronic acid) Drug Profile1091
  4-P004 Drug Profile1101
  ABT-981 Drug Profile1111
  ALLO-ASC Drug Profile1121
  AlloJoin Drug Profile1131
  AM-3701 Drug Profile1141
  AM-3876 Drug Profile1151
  Anatabine Drug Profile1163
  Antibody for Osteoarthritis Drug Profile1191
  Antibody to Inhibit TGF-Beta 1 for Osteoarthritis Drug Profile1201
  ARC-118 Drug Profile1211
  AS-001 Drug Profile1221
  ASP-7962 Drug Profile1231
  BNP-OA Drug Profile1241
  BRM-421 Drug Profile1251
  CDX-085 Drug Profile1262
  celecoxib Drug Profile1281
  CHND-1 Drug Profile1291
  clodronate disodium Drug Profile1301
  CR-8357 Drug Profile1311
  CRB-0017 Drug Profile1321
  CS-30MS02 Drug Profile1331
  DA-5202 Drug Profile1341
  denosumab Drug Profile1359
  DIS-BIO-EPS Drug Profile1441
  DNX-314 Drug Profile1451
  Drug for Bone Diseases and Osteoarthritis Drug Profile1461
  Drug for Osteoarthritis Drug Profile1471
  Drugs to Inhibit Renin Angiotensin for Osteoarthritis Drug Profile1481
  Drugs to Modulate Bone Morphogenetic Protein for Osteoarthritis and Fracture Drug Profile1491
  Drugs to Modulate PPAR-Delta for Immunology, Metabolic and Musculoskeletal Disorders Drug Profile1501
  fasitibant chloride Drug Profile1511
  GLPG-1972 Drug Profile1521
  GQ-203 Drug Profile1531
  GQ-303 Drug Profile1541
  GSK-2394002 Drug Profile1551
  JD-4000 Series Drug Profile1561
  JTA-004 Drug Profile1571
  Kartogenin Drug Profile1581
  KBP-056 Drug Profile1591
  ketoprofen Drug Profile1602
  KM-278 Drug Profile1621
  LEVI-04 Drug Profile1631
  LH-023 Drug Profile1641
  LNA-043 Drug Profile1651
  MIV-711 Drug Profile1662
  Monoclonal Antibodies for Inflammation and Osteoarthritis Drug Profile1681
  Monoclonal Antibody Conjugates for Osteoarthritis Drug Profile1691
  Monoclonal Antibody for Osteoarthritis Drug Profile1701
  MOR-106 Drug Profile1711
  MPC-75IA Drug Profile1721
  naproxcinod Drug Profile1733
  NBS-101 Drug Profile1761
  NStride APS Drug Profile1771
  ONO-4474 Drug Profile1781
  OTXCP-03 Drug Profile1791
  OTXCP-07 Drug Profile1801
  Peptide for Osteoarthritis Drug Profile1811
  PF-152 Drug Profile1821
  piclidenoson Drug Profile1837
  PL-1100 Drug Profile1901
  PN-6047 Drug Profile1911
  PRO-1 Drug Profile1921
  Progenza Drug Profile1931
  Protein for Osteoarthritis and Asthma Drug Profile1941
  Protein for Rheumatoid Arthritis and Osteoarthritis Drug Profile1951
  Protein to Activate BMP-7 for Kidney Diseases, Metabolic Disorders and Osteoarthritis Drug Profile1962
  PRX-167700 Drug Profile1981
  Recombinant Peptides for Osteoarthritis Drug Profile1991
  Recombinant Protein for Osteoarthritis Drug Profile2001
  Recombinant Protein to Agonize IGF-1 Receptor for Osteoarthritis Drug Profile2011
  Recombinant Protein to Agonize IL-4 and IL-10 Receptors for Osteoarthritis and CNS Drug Profile2021
  ReJoin Drug Profile2034
  Salmon Calcitonin Drug Profile2072
  SB-061 Drug Profile2091
  SBL-005 Drug Profile2101
  SI-613 Drug Profile2111
  SM-04690 Drug Profile2122
  Small Molecule for Degenerative Arthritis Drug Profile2141
  Small Molecule to Agonize A2A for Immunology, Hematological and Neurological Disorders Drug Profile2151
  Small Molecule to Target GPR22 for Anxiety, Cardiovascular Diseases and Osteoarthritis Drug Profile2161
  Small Molecules for Immunology, Metabolic and Musculoskeletal Disorders Drug Profile2171
  Small Molecules for Immunology, Musculoskeletal and Metabolic Disorders Drug Profile2181
  Small Molecules for Osteoarthritis Drug Profile2191
  Small Molecules to Antagonize TNFR1 for Immunology, Gastrointestinal, Neurology and Hematological Disorders Drug Profile2201
  Small Molecules to Inhibit ADAMTS-5 for Osteoarthritis Drug Profile2211
  Small Molecules to Inhibit iNOS for Osteoarthritis Drug Profile2221
  Small Molecules to Inhibit MMP-13 for Osteoarthritis Drug Profile2231
  sprifermin Drug Profile2242
  Stem Cell Therapy for Articular Cartilage Lesions and Osteoarthritis Drug Profile2261
  Stem Cell Therapy for Autoimmune Diseases Drug Profile2272
  Stem Cell Therapy for CNS Disorders, Rheumatoid Arthritis, Osteoarthritis, Bronchopulmonary Dysplasia and Heart Failure Drug Profile2291
  Stem Cell therapy for CNS, CVS, Dermatological, Immunological and Metabolic Disorders Drug Profile2301
  Stem Cell Therapy for Osteoarthritis Drug Profile2311
  Stem Cell Therapy for Osteoarthritis and Rheumatoid Arthritis Drug Profile2321
  Stem Cell Therapy for Osteoarthritis, Diabetes Mellitus, Acute Liver Failure and Neurodegenerative Diseases Drug Profile2331
  Sulforadex Drug Profile2342
  tonogenchoncel-L Drug Profile2363
  TPX-100 Drug Profile2392
  TRBN-0224 Drug Profile2412
  UGP-302 Drug Profile2432
  VOLT-01 Drug Profile2451
  X-0002 Drug Profile2462
  XT-101 Drug Profile2481
  XT-150 Drug Profile2491
  YH-14619 Drug Profile2501
  YRA-1909 Drug Profile2511
  YY-1201 Drug Profile2521
  ZYN-002 Drug Profile2533
Osteoarthritis Dormant Projects25610
Osteoarthritis Discontinued Products2662
Osteoarthritis Product Development Milestones26812
  Featured News &Press Releases2681
    Jun 27, 2016: Zynerba Pharmaceuticals Announces Positive Top Line Results from ZYN002 CBD Gel Phase 1 Multiple Rising Dose Trial and Initiation of Phase 2 Study in Adult Epilepsy Patients with Refractory Focal Seizures2681
    Jun 13, 2016: Symic Advances Product Candidate SB-061 into Clinical Development for the Treatment of Osteoarthritis2691
    May 17, 2016: Regeneus completes enrolment, positive safety review in stem cell trial2701
    May 05, 2016: Rock Creek Pharmaceuticals Announces Japanese, European and U.S. Patent Developments and Valuation Initiative for Lead Compound2711
    Apr 12, 2016: Cannabis and Cannabinoid Research Publishes Data Demonstrating the Degradation of Cannabidiol to Psychoactive Cannabinoids when Exposed to Simulated Gastric Fluid2721
    Apr 01, 2016: Mesoblast Cell Therapy Shows Disease Modifying Effects On Knee Osteoarthritis2731
    Feb 16, 2016: Regenerative Medicine Company, TissueGene, adds Dr. Gurdyal Kalsi as Chief Medical Officer2741
    Jan 28, 2016: Medivir initiates phase IIa study of MIV-711 in knee osteoarthritis2751
    Jan 13, 2016: Cellular Biomedicine Group Announces Positive 48-Week Data from Phase IIb Clinical Trial for Knee Osteoarthritis Stem Cell ReJoin Therapy2751
    Jan 06, 2016: Launch of Phase I clinical Trial for AlloJoin Off-the-Shelf Allogeneic Stem Cell Therapy for KOA2761
    Jan 06, 2016: Zynerba Pharmaceuticals Announces Positive Initial Results From ZYN002 CBD Gel Phase 1 Single Rising Dose Trial and Initiation of Phase 1 Multiple Rising Dose Trial2771
    Dec 22, 2015: Upcoming Presentation to Release 48-Week Data From Phase IIb Clinical Trial for ReJoin2781
    Dec 16, 2015: Symic Receives New U.S. Patent for Osteoarthritis Program2781
    Nov 20, 2015: Galapagos initiates Phase 1 First-in-Human study with GLPG1972, receives EU3.5 million milestone from Servier2781
    Nov 17, 2015: Symic Biomedical Selects Osteoarthritis Clinical Candidate2791
Appendix2802
  Methodology2801
  Coverage2801
  Secondary Research2801
  Primary Research2801
  Expert Panel Validation2801
  Contact Us2801
  Disclaimer2811

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Osteoarthritis - Pipeline Review, H2 2016" Aug 24, 2016. Alacra Store. May 15, 2025. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Osteoarthritis-Pipeline-Review-H2-2016-2088-16429>
  
APA:
Global Markets Direct - Market Research. (2016). Osteoarthritis - Pipeline Review, H2 2016 Aug 24, 2016. New York, NY: Alacra Store. Retrieved May 15, 2025 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Osteoarthritis-Pipeline-Review-H2-2016-2088-16429>
  
US$ 2,000.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.